WASHINGTON - A key advisory committee to the U.S. Food and Drug Administration on Thursday is set to vote on whether to recommend the approval of Moderna’s COVID-19 vaccine, one of the final hurdles before a second shot could be distributed in the United States.The two-dose vaccine, from Moderna and the National Institutes of Health, was found to be more than 94% effective in preventing COVID-19 for individuals 18 and older.
Earlier this week, the FDA released a preliminary analysis confirming the shot’s effectiveness and safety.The independent panel of outside experts will next review the data available during an all-day meeting.